1.09 (6.76%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Very Weak
Earnings
Very Strong
Earnings
Strong
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
Lyell Immunopharma, Inc.
Telephone
1.650.695.0677
Address
Suite 101, 201 Haskins Way, South San Francisco, CA 94080
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 7.65 - 45
Trade Value (12mth)
US$430,211.00
1 week
-9.99%
1 month
-32.52%
YTD
-44.34%
1 year
96.71%
All time high
396.80
EPS 3 yr Growth
8.30%
EBITDA Margin
NaN%
Operating Cashflow
-$150m
Free Cash Flow Return
-41.40%
ROIC
-75.80%
Interest Coverage
0.00
Quick Ratio
5.30
Shares Outstanding (Fully Diluted)
22m
HALO Sector
Healthcare
Next Company Report Date
03-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 14 May 26 | |
| 14 May 26 | |
| 07 May 26 | |
| 07 May 26 | |
| 07 May 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -18.7 | -26.23 | -16.06 | | | | ||
EPS (Fully Diluted) | $ | | | | | -18.7 | -26.23 | -16.06 | | | | ||
Growth | % | | | | | -26.1 | -40.3 | 38.8 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
